(Updates with comment from analyst in the fourth paragraph).
April 15 (Bloomberg) - Johnson & Johnson is in talks to buy Synthes Inc., the largest maker of devices to treat bone fractures and trauma, said a person informed about the discussions.An agreement is and remains days or weeks, said the person, who spoke condition of anonymity because the talks are private. With a current market capitalization of Synthes 16.4 billion Swiss francs ($18.4 billion), the acquisition can be the most important in the history of Johnson & Johnson.Synthes would give focused on New Brunswick, New Jersey, J & J vis hipplates, surgical power tools and instruments to deal with the injuries of the spine and the soft tissues that generated 3.69 billion in sales last year. J & J, major manufacturer the more artificial hips, saw joint-implant income fall during the fourth quarter of last year, injured by dragging the economy on medical procedures and a reminder of the hips used in 93 000 patients.The acquisition would be "a good deal" for J & J, giving it a market access more rapidly that the undertaking of the hip and the knee, said Jeff Jonas, an analyst with Gabelli & Co. in New York, in a telephone interview. Skeletal trauma ", it is more a specialty niche that has not attracted many players and Synthes is the dominant presence in this market.".William Price, a spokesman for J & J, refused to comment after the Wall Street Journal reported the talks, earlier today. Calls to West Chester, Pennsylvania, Office where Synthes is based were returned to the investor relations office the company in Zurich. Left after normal office hours telephone message was not immediately returned.-Editors: Jennifer Sondag, Andrew Pollack
To contact the reporters on this story: Alex Nussbaum in New York anussbaum1@bloomberg.net Zachary Mider in New York to the zmider1@bloomberg.net
To contact the responsible editors of this story: Jennifer Sondag to jsondag@bloomberg.net; Reg Gale in New York to the rgale5@bloomberg.net
没有评论:
发表评论